Merck & Co. (MRK) FY2025 10-K Annual Report
Merck & Co. (MRK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Merck & Co. FY2025 10-K Analysis
Business Overview
- • Global pharma/animal health company; Pharmaceutical segment (89% of sales) anchored by Keytruda immunotherapy franchise generating $31.7B in FY2025
- • Keytruda Qlex (subcutaneous pembrolizumab) launched in 2025; FDA-approved September 2025 across most adult solid tumor indications — new formulation extending franchise runway beyond 2028 Keytruda compound patent expiry
- • Gardasil revenue collapsed to $5.2B from $8.6B (-39% YoY) driven by China market contraction; Winrevair (PAH) debuted at $1.4B vs zero in 2024, partially offsetting Gardasil decline
- • ~75,000 employees globally as of Dec 31, 2025; US international sales mix shifted to 56% domestic / 44% international vs 50/50 in 2024, reflecting China Gardasil erosion
- • December 2025: Merck signed a "Most-Favored-Nation" agreement with the US government — committing to direct-to-patient pricing, Medicaid discounts, and MFN-linked launch pricing for new products in exchange for a 3-year Section 232 tariff delay on manufacturing imports
Management Discussion & Analysis
- • Revenue $65.0B in 2025, up 1% YoY (+2% ex-FX) from $64.2B; US sales +13% to $36.5B, international -11% to $28.5B
- • Gross margin 74.8% vs 76.3% in 2024; GAAP EPS $7.28 vs $6.74; non-GAAP EPS $8.98 vs $7.65
- • Best segment: Pharmaceutical (Keytruda/Keytruda Qlex $31.7B, +7%; Welireg +41%); worst: Vaccines, with Gardasil/Gardasil 9 -39% to $5.2B on China demand collapse
- • Operating cash flow $16.5B (vs $21.5B in 2024); capex $4.1B; dividends $8.2B; buybacks $5.1B (~59M shares); quarterly dividend raised to $0.85/share
- • Key risks: Keytruda IRA government price-setting effective 2029, Januvia/Janumet US exclusivity loss May/Jul 2026, $9.2B Cidara acquisition closing Jan 2026 with ~$9.0B R&D charge expected Q1 2026
Risk Factors
- • IRA price setting: Keytruda (49% of total 2025 sales) expected selected by HHS in 2027, government price effective Jan 1, 2029, U.S. sales to decline materially
- • Gardasil/Gardasil 9 China shipments paused since Feb 2025; local competitor's nine-valent HPV vaccine approved June 2025 for females 9-45 years
- • Keytruda biosimilar competition expected Dec 2028 when primary compound patent expires, with European market exclusivity lost 2031
- • Bridion loses U.S. exclusivity July 2026; Januvia/Janumet loses exclusivity May 2026; Company expects to lose "nearly all" U.S. Januvia/Janumet sales thereafter
- • IRS examining 2017-2018 tax returns including TCJA one-time transition tax position; adverse outcome described as potentially material to cash flows
Merck & Co. FY2025 Key Financial MetricsXBRL
Revenue
$65.0B
▲ +1.3% YoY
Net Income
$18.3B
▲ +6.6% YoY
Net Margin
28.1%
▲ +140bp YoY
ROE
34.7%
▼ -226bp YoY
Total Assets
$136.9B
▲ +16.9% YoY
EPS (Diluted)
$7.28
▲ +8.0% YoY
Operating Cash Flow
$16.5B
▼ -23.3% YoY
Source: XBRL data from Merck & Co. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Merck & Co. Annual Reports
Get deeper insights on Merck & Co.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.